font size
Sign inprintPrint

CAPITAL MARKETS:

Actavis-Allergan Deal Continues Record Year of M&A

Increasingly Competitive Environment for Sought-After Assets Pushes Prices Higher, Says Burrill Media.


SAN FRANCISCO—December 1, 2014—Actavis agreement to acquire Botox-maker Allergan for $66 billion topped another big month for life sciences M&A activity in what is already a record year of dealmaking. The agreement helped boost total M&A life sciences activity through the first 11 months of 2014 to a record $340.8 billion, up from $118.3 billion for the same period a year ago and well beyond the previous record set in 2009 of $189.7 billion for M&A transactions involving therapeutics, tools, diagnostics, and digital health companies, according to Burrill Media. Read More
Other recent stories


Follow burrillreport on Twitter